Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty

A Bayes-Genis, RS Schwartz, DA Lewis… - … , and vascular biology, 2001 - Am Heart Assoc
A Bayes-Genis, RS Schwartz, DA Lewis, MT Overgaard, M Christiansen, C Oxvig, K Ashai…
Arteriosclerosis, thrombosis, and vascular biology, 2001Am Heart Assoc
Insulin-like growth factor (IGF)-I stimulates vascular smooth muscle cell (VSMC) migration
and proliferation, which are fundamental to neointimal hyperplasia in postangioplasty
restenosis. IGF-I action is modulated by several high-affinity IGF binding proteins (IGFBPs).
IGFBP-4 is the predominant IGFBP produced by VSMCs and is a potent inhibitor of IGF-I
action. However, specific IGFBP-4 proteases can cleave IGFBP-4 and liberate active IGF-I. In
this study, we document IGFBP-4 protease produced by human and porcine coronary artery …
Abstract
—Insulin-like growth factor (IGF)-I stimulates vascular smooth muscle cell (VSMC) migration and proliferation, which are fundamental to neointimal hyperplasia in postangioplasty restenosis. IGF-I action is modulated by several high-affinity IGF binding proteins (IGFBPs). IGFBP-4 is the predominant IGFBP produced by VSMCs and is a potent inhibitor of IGF-I action. However, specific IGFBP-4 proteases can cleave IGFBP-4 and liberate active IGF-I. In this study, we document IGFBP-4 protease produced by human and porcine coronary artery VSMCs in culture as pregnancy-associated plasma protein-A (PAPP-A). This was shown by a distinctive IGFBP-4 cleavage pattern, specific inhibition of IGFBP-4 protease activity with PAPP-A polyclonal antibodies, and immunorecognition of PAPP-A by monoclonal antibodies. Furthermore, we found a 2-fold increase in IGFBP-4 protease activity in injured porcine VSMC cultures in vitro (P<0.05). We also evaluated IGFBP-4 protease/PAPP-A expression in vivo after coronary artery balloon injury. Twenty-five immature female pigs underwent coronary overstretch balloon injury, and vessels were examined at defined time points after the procedure. Abundant PAPP-A expression was observed in the cytoplasm of medial and neointimal cells 7, 14, and 28 days after angioplasty (P<0.01 vs control). The highest PAPP-A labeling indices were located in the neointima (36.1±2.1%) and the media (31.7±1.2%) 28 days after injury. Western blot analysis confirmed increased PAPP-A in injured vessels. PAPP-A, a regulator of IGF-I bioavailability through proteolysis of IGFBP-4, is thus expressed by VSMCs in vitro and in restenotic lesions in vivo. These results suggest a possible role for PAPP-A in neointimal hyperplasia.
Am Heart Assoc